# Early ART to Limit Infection and Establishment of Reservoir

> **NCT02859558** · PHASE2 · COMPLETED · sponsor: **Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections** · enrollment: 195 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy

## Key facts

- **NCT ID:** NCT02859558
- **Lead sponsor:** Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-24
- **Primary completion:** 2020-12-02
- **Final completion:** 2025-04-16
- **Target enrollment:** 195 (ACTUAL)
- **Last updated:** 2025-08-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02859558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02859558, "Early ART to Limit Infection and Establishment of Reservoir". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02859558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*